Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
POH1 siRNA is a small interfering RNA designed to silence the expression of the POH1 gene (also known as PSMD14 or Rpn11). POH1 is a highly conserved deubiquitinating enzyme (DUE) that serves as a critical component of the 19S proteasome lid, where it facilitates protein degradation by removing ubiquitin chains from substrates. In oncology research, POH1 knockdown has been shown to inhibit tumor cell proliferation and induce apoptosis via the mitochondrial pathway, often involving the stabilization of p53 and Bim. While primarily used as a research reagent in laboratory settings, preclinical studies have explored its therapeutic potential through intratumoral delivery in models of hepatocellular carcinoma, esophageal cancer, and colorectal cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on POH1 siRNA.